Body Self-image Disturbances in Women with Prolactinoma

Overview

Journal Braz J Psychiatry

Specialty Psychiatry

Date 2019 Jul 18

PMID 31314867

Citations 1

Authors

Helen S Pereira

Erika C Naliato

Aline B Moraes

Monica R Gadelha

Leonardo Vieira Neto

Renan M Almeida

Antonio E Nardi

Alice H Violante

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate body dissatisfaction and distorted body self-image in women with prolactinoma.

Methods: Body dissatisfaction and distorted body self-image were evaluated in 80 women with prolactinoma. All patients were in menacme, 34% had normal body mass index (BMI), and 66% were overweight. Most patients (56.2%) had normal prolactin (PRL) levels and no hyperprolactinemia symptoms (52.5%). The Body Shape Questionnaire (BSQ) was used to assess the patients' dissatisfaction with and concern about their physical form, and the Stunkard Figure Rating Scale (FRS) was used to assess body dissatisfaction and distorted body self-image. The patients were divided according to PRL level (normal vs. elevated) and the presence or absence of prolactinoma symptoms.

Results: The normal and elevated PRL groups had similar incidences of body dissatisfaction and distorted body self-image. However, symptomatic patients reported a higher incidence of dissatisfaction than asymptomatic patients. Distorted body self-image was less common among symptomatic patients.

Conclusion: Symptomatic patients showed higher body dissatisfaction, but lower body self-image distortion. The presence of symptoms may have been responsible for increased body awareness. The perception of body shape could have triggered feelings of dissatisfaction compared to an ideal lean body. Therefore, a distorted body self-image might not necessarily result in body dissatisfaction in women with prolactinomas.

Citing Articles

A study on the correlations of PRL levels with anxiety, depression, sleep, and self-efficacy in patients with prolactinoma.

Miao X, Fu Z, Luo X, Wang J, Yuan L, Zhao S Front Endocrinol (Lausanne). 2024; 15:1369729.

PMID: 38572480 PMC: 10989272. DOI: 10.3389/fendo.2024.1369729.

References

Cesar de Oliveira Naliato E, Violante A, Caldas D, Lamounier Filho A, Rezende Loureiro C, Fontes R . Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary. 2008; 11(3):247-54. DOI: 10.1007/s11102-008-0091-9. View

Sonino N, Navarrini C, Ruini C, Fallo F, Boscaro M, Fava G . Life events in the pathogenesis of hyperprolactinemia. Eur J Endocrinol. 2004; 151(1):61-5. DOI: 10.1530/eje.0.1510061. View

Di Pietro M, da Silveira D . Internal validity, dimensionality and performance of the Body Shape Questionnaire in a group of Brazilian college students. Braz J Psychiatry. 2008; 31(1):21-4. DOI: 10.1590/s1516-44462008005000017. View

Sonino N, Fava G . Improving the concept of recovery in endocrine disease by consideration of psychosocial issues. J Clin Endocrinol Metab. 2012; 97(8):2614-6. DOI: 10.1210/jc.2012-1710. View

Kakeshita I, Almeida S . [Relationship between body mass index and self-perception among university students]. Rev Saude Publica. 2006; 40(3):497-504. DOI: 10.1590/s0034-89102006000300019. View

Sobrinho L . Prolactin, psychological stress and environment in humans: adaptation and maladaptation. Pituitary. 2003; 6(1):35-9. DOI: 10.1023/a:1026229810876. View

Romijn J . Hyperprolactinemia and prolactinoma. Handb Clin Neurol. 2014; 124:185-95. DOI: 10.1016/B978-0-444-59602-4.00013-7. View

Kars M, van der Klaauw A, Onstein C, Pereira A, Romijn J . Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol. 2007; 157(2):133-9. DOI: 10.1530/EJE-07-0259. View

Shibli-Rahhal A, Schlechte J . The effects of hyperprolactinemia on bone and fat. Pituitary. 2008; 12(2):96-104. DOI: 10.1007/s11102-008-0097-3. View

10.

Cesar de Oliveira Naliato E, Violante A, Caldas D, Farias M, Bussade I, Lamounier Filho A . Bone density in women with prolactinoma treated with dopamine agonists. Pituitary. 2007; 11(1):21-8. DOI: 10.1007/s11102-007-0064-4. View

11.

Mancini T, Casanueva F, Giustina A . Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008; 37(1):67-99, viii. DOI: 10.1016/j.ecl.2007.10.013. View

12.

Creemers L, Zelissen P, Van T Verlaat J, Koppeschaar H . Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh). 1991; 125(4):392-6. DOI: 10.1530/acta.0.1250392. View

13.

Braucks G, Cesar de Oliveira Naliato E, Tabet A, Gadelha M, Violante A . [Clinical and therapeutic aspects of prolactinoma in men]. Arq Neuropsiquiatr. 2004; 61(4):1004-10. DOI: 10.1590/s0004-282x2003000600022. View

14.

Crespo I, Valassi E, Santos A, Webb S . Health-related quality of life in pituitary diseases. Endocrinol Metab Clin North Am. 2015; 44(1):161-70. DOI: 10.1016/j.ecl.2014.10.013. View

15.

Sobrinho L . Emotional aspects of hyperprolactinemia. Psychother Psychosom. 1998; 67(3):133-9. DOI: 10.1159/000012273. View

16.

Mechanic D . Sociological dimensions of illness behavior. Soc Sci Med. 1995; 41(9):1207-16. DOI: 10.1016/0277-9536(95)00025-3. View

17.

Fava G, Fava M, Kellner R, Serafini E, MASTROGIACOMO I . Depression hostility and anxiety in hyperprolactinemic amenorrhea. Psychother Psychosom. 1981; 36(2):122-8. DOI: 10.1159/000287535. View

18.

Glezer A, Bronstein M . [Prolactinoma]. Arq Bras Endocrinol Metabol. 2014; 58(2):118-23. DOI: 10.1590/0004-2730000002961. View

19.

Naliato E, Violante A, Caldas D, Lamounier Filho A, Loureiro C, Fontes R . Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf). 2007; 67(6):845-52. DOI: 10.1111/j.1365-2265.2007.02973.x. View

20.

Nunes M, Sobrinho L, Calhaz-Jorge C, Santos M, Mauricio J, Sousa M . Psychosomatic factors in patients with hyperprolactinemia and/or galactorrhea. Obstet Gynecol. 1980; 55(5):591-5. View